FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
August 21, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial
New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET
August 09, 2024 09:30 ET
|
FMW Media Works Corp
New to The Street TV Announces Episode 583, Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024
BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
July 30, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia, Inc., today reported it has submitted a 510(k) for approval of its patented Morph® DNA™ Steerable Introducer Sheath with the FDA.
Truveta announces support for regulatory submissions to the FDA and global regulatory authorities
June 18, 2024 11:13 ET
|
Truveta
BELLEVUE, Wash., June 18, 2024 (GLOBE NEWSWIRE) -- Today, Truveta announced regulatory and audit capabilities to support its customers for real-world evidence (RWE) submissions to the Food and Drug...
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
March 13, 2024 09:00 ET
|
Femasys Inc.
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET...
Beam Global Announces New Federal Customers Placed First-Time Orders for EV ARC Solar-Powered EV Charging Systems
February 13, 2024 06:00 ET
|
Beam Global
Beam Global Announces New Federal Customers Placed First-Time Orders for EV ARC Solar-Powered EV Charging Systems
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
February 08, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions...
Robbins LLP Reminds Brainstorm Cell Therapeutics Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Against BCLI
December 15, 2023 17:36 ET
|
Robbins LLP
Brainstorm Cell Therapeutics Inc. (BCLI) Misled Investors About the Viability and Efficacy of its drug NurOwn
New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT
December 01, 2023 09:30 ET
|
FMW Media Works Corp
New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
November 14, 2023 07:15 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...